My lab utilizes novel techniques in combinatorial and computational chemistry for the identification of hit compounds as well as hit to lead optimization. We employee technologies that allow for the rapid assessment of millions of small molecules and peptides using exponentially less samples. The technology can be applied to virtually any assay paradigm. We currently have active programs in the areas of obesity, cachexia, neurite outgrowth, tachyphylaxis, diabetic kidney disease, and bacterial resistance. We are always open to new collaborations as well as discussing advancements in the use of our core capabilities.
